BSX

Boston Scientific occupies a peculiar position in the medical device landscape: it is simultaneously one of the most acquisitive companies in healthcare and one of the most structurally durable. Over the past decade, the company has executed a transformation from a struggling cardiac device maker, recovering from product recalls and litigation crises, into a diversified interventional platform spanning cardiology, urology, endoscopy, neuromodulation, and peripheral interventions. The scale of this transformation is underappreciated. In 2014, Boston Scientific was a company investors avoided. By 2025, it had become one of the highest-performing large-cap medical device stocks in the world, outpacing peers like Medtronic and Abbott on both revenue growth and margin expansion.

The central analytical question for Boston Scientific is not whether its products are competitive. They demonstrably are. The question is whether the company's growth, which has been driven substantially by acquisitions and new product launches in high-growth interventional categories, represents a durable structural advantage or a well-executed but ultimately exhaustible playbook. Put differently: does Boston Scientific have a compounding moat, or does it have a superior management team executing a finite strategy?

The answer lies in an often-overlooked structural dynamic. Boston Scientific does not compete primarily on the basis of any single product or therapy. It competes on the basis of procedural infrastructure. Hospitals do not buy a Boston Scientific device; they adopt a Boston Scientific procedural ecosystem, from the catheter to the imaging integration to the post-procedure monitoring pathway. This is a company that has made itself difficult to remove from the cath lab, the endoscopy suite, and the electrophysiology lab not because of any single product's superiority, but because of the density of its presence across the procedural workflow. That density is the moat, and it is widening.

The timing of this analysis matters. Boston Scientific's recent acquisitions, including the landmark Axonics deal in the urology space and continued expansion of its electrophysiology portfolio through the FARAPULSE pulsed field ablation (PFA) platform, have positioned the company at the intersection of several of the fastest-growing procedural markets in medicine. The question for 2026 is whether these bets, now largely integrated, will deliver the compounding returns that the current valuation implies.